Gardasil

Ufovax Announces Its Self-Assembling NanoParticles as the Next-Generation Vaccine Solution for COVID-19

Friday, September 18, 2020 - 12:32am

Ufovax holds an exclusive global license to the Scripps Intellectual Property covering the platform and several vaccines, including COVID-19.

Key Points: 
  • Ufovax holds an exclusive global license to the Scripps Intellectual Property covering the platform and several vaccines, including COVID-19.
  • In a publication submitted Monday, September 14 (now available on the bioRxiv preprint server ), the authors present a systematic study on rational vaccine design and evaluation of vaccine response in mice.
  • In particular, Zhu and his team propose a new spike antigen design (S2GHR2) and displayed it on several SApNPs as COVID-19 vaccine candidates.
  • In practice, we have seen similar performance from the Merck HPV Gardasil vaccine which is essentially a protein nanoparticle vaccine.

Baum Hedlund Files Gardasil Lawsuit Against Merck on Behalf of Man

Thursday, September 17, 2020 - 12:56am

ORANGE COUNTY, Calif., Sept. 16, 2020 /PRNewswire/ -- Baum Hedlund Aristei & Goldman filed aGardasil vaccine injury lawsuit today against manufacturer Merck on behalf of a young man who sustained life-altering injuries he alleges were caused by the HPV vaccine.

Key Points: 
  • ORANGE COUNTY, Calif., Sept. 16, 2020 /PRNewswire/ -- Baum Hedlund Aristei & Goldman filed aGardasil vaccine injury lawsuit today against manufacturer Merck on behalf of a young man who sustained life-altering injuries he alleges were caused by the HPV vaccine.
  • But Merck knew that Gardasil was neither safe nor effective at preventing cervical cancer, and worse, the company knew that Gardasil could cause a host of serious health issues."
  • Baum Hedlund Aristei & Goldmanis one of the nation's leading law firms representing victims who have sustained injuries after receiving the Gardasil HPV vaccine .
  • Since 1973, Baum Hedlund Aristei & Goldman has won over $4 billion in settlements and verdicts on behalf of clients across all areas of practice.

Worldwide Human Papillomavirus (HPV) Vaccines Overview 2020 - Pipeline & Marketed Vaccines, Regulatory Events, Clinical Trial Landscape, Future Trends, KOL Insights, Unmet Needs, Sales (2015-2024)

Thursday, June 18, 2020 - 9:30pm

DUBLIN, June 18, 2020 /PRNewswire/ -- The "Disease Analysis: Human Papillomavirus (HPV) Vaccines" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, June 18, 2020 /PRNewswire/ -- The "Disease Analysis: Human Papillomavirus (HPV) Vaccines" report has been added to ResearchAndMarkets.com's offering.
  • Worldwide vaccination programs for human papillomavirus (HPV) have evolved substantially over the last decade.
  • Both vaccines are based on the recombinant expression of major capsid antigen L1 from different HPV serotypes, which self-assemble into virus-like particles (VLPs).
  • In 2014, Gardasil 9, a nine-valent vaccine capable of protecting from an additional 20% of HPV-related cancers, superseded Gardasil.

2020 Disease Analysis Report: Human Papillomavirus (HPV) Vaccines - ResearchAndMarkets.com

Monday, June 15, 2020 - 12:11pm

The "Disease Analysis: Human Papillomavirus (HPV) Vaccines" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Disease Analysis: Human Papillomavirus (HPV) Vaccines" report has been added to ResearchAndMarkets.com's offering.
  • Worldwide vaccination programs for human papillomavirus (HPV) have evolved substantially over the last decade.
  • Both vaccines are based on the recombinant expression of major capsid antigen L1 from different HPV serotypes, which self-assemble into virus-like particles (VLPs).
  • In 2014, Gardasil 9, a nine-valent vaccine capable of protecting from an additional 20% of HPV-related cancers, superseded Gardasil.

FDA Approves Merck’s GARDASIL 9 for the Prevention of Certain HPV-Related Head and Neck Cancers

Friday, June 12, 2020 - 11:40pm

The oropharyngeal and head and neck cancer indication is approved under accelerated approval based on effectiveness in preventing HPV-related anogenital disease.

Key Points: 
  • The oropharyngeal and head and neck cancer indication is approved under accelerated approval based on effectiveness in preventing HPV-related anogenital disease.
  • Todays approval for the prevention of HPV-related oropharyngeal and other head and neck cancers represents an important step in Mercks mission to help reduce the number of men and women affected by certain HPV-related cancers.
  • But, for those who don't clear the virus, it can cause certain cancers.
  • GARDASIL 9 does not eliminate the necessity for vaccine recipients to undergo screening for cervical, vulvar, vaginal, anal, oropharyngeal and other head and neck cancers as recommended by a healthcare provider.

Global Human Papillomavirus (HPV) Testing Market Outlook and Forecast 2020-2025 - ResearchAndMarkets.com

Tuesday, March 3, 2020 - 10:17am

The global HPV testing market is expected to grow at a CAGR of over 12% during the period 2019-2025.

Key Points: 
  • The global HPV testing market is expected to grow at a CAGR of over 12% during the period 2019-2025.
  • The analysis of the global HPV testing market provides sizing and growth opportunities for the forecast period 2020-2025.
  • The increased procurement of the latest-generation HPV testing analyzers and test kits, coupled with the high prevalence of HPV-related infections and cancers, especially cervical and vaginal, influences the growth of the global HPV testing market.
  • Healthcare professionals in hospitals use human papillomavirus testing as a screening procedure for the cervical and other related cancers.

Socioeconomic Factors Increasing Cervical Cancer Rates for Some in the U.S. Despite Downward Nationwide Trends

Thursday, January 23, 2020 - 2:00pm

To prevent these results, it is crucial that women keep themselves informed as recent cervical cancer testing recommendations2 and HPV vaccination age limits3 have changed.

Key Points: 
  • To prevent these results, it is crucial that women keep themselves informed as recent cervical cancer testing recommendations2 and HPV vaccination age limits3 have changed.
  • View the full release here: https://www.businesswire.com/news/home/20200123005041/en/
    There are nearly 12,000 new cases of cervical cancer being diagnosed in the U.S. each year, but steps can be taken to help women prevent cervical cancer.
  • The U.S. Department of Health and Human Services recommends the following steps to help prevent cervical cancer 4:
    Get the HPV vaccine.
  • These tests can help find cervical cells that are infected with HPV or have other abnormalities before they turn into cervical cancer.

Icosavax Launches with $51 Million Series A Financing to Advance Computationally Designed VLP Vaccines

Thursday, October 3, 2019 - 2:00pm

VLPs contain no genetic material, so they are non-infectious and can provide a safer alternative to live-attenuated or inactivated vaccines.

Key Points: 
  • VLPs contain no genetic material, so they are non-infectious and can provide a safer alternative to live-attenuated or inactivated vaccines.
  • Naturally occurring VLPs have delivered successful vaccines, including Gardasil and Cervarix against human papillomavirus (HPV) and Engerix-B and Recombivax HB against Hepatitis B.
  • Ralf developed and brought to licensure more than 25 different vaccines and has published extensively on vaccines and public health.
  • Icosavax is focused on developing safe and effective vaccines against infectious diseases that address important unmet medical needs and reduce healthcare costs.

CDC Advisory Committee on Immunization Practices (ACIP) Votes to Provisionally Recommend Shared Clinical Decision-Making for Vaccination of Adults Ages 27-45 with GARDASIL®9 & Harmonization of Catch-up Vaccination for Males and Females Through Age 26

Wednesday, June 26, 2019 - 9:45pm

The ACIP also voted to expand routine and catch-up recommendations for males through 26 years of age who are not adequately vaccinated.

Key Points: 
  • The ACIP also voted to expand routine and catch-up recommendations for males through 26 years of age who are not adequately vaccinated.
  • The CDC currently recommends routine vaccination of females and males 11-12 years of age, and vaccination can begin at age 9.
  • In the U.S., almost half of new HPV infections occur in adults 25 years of age or older.
  • The nine types of HPV covered in GARDASIL 9 cause the majority of HPV-related cancers and other diseases in women and men.

CDC's Advisory Committee for Immunization Practices (ACIP) Considers Expanding Recommendations for Human Papilloma Virus (HPV) Vaccine to Include Ages 27 to 45

Tuesday, February 26, 2019 - 10:48pm

WASHINGTON, Feb. 26, 2019 /PRNewswire/ --CDC's ACIP committee will consider recommending the HPV vaccine to men and women ages 27 to 45.

Key Points: 
  • WASHINGTON, Feb. 26, 2019 /PRNewswire/ --CDC's ACIP committee will consider recommending the HPV vaccine to men and women ages 27 to 45.
  • This recommendation would potentially expose over 80 million adults to the Gardasil 9 vaccine.
  • Kennedy states that CHD considers an expansion of the HPV recommendations reckless and outlined numerous reasons to support his concerns.
  • A government funded study established that the voluntary VAERS system captures less than 1% of vaccine injuries and deaths.